Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $BSX
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/10/2025 | $108.00 | Hold → Buy | Deutsche Bank |
10/18/2024 | Buy → Hold | Needham | |
5/30/2024 | $90.00 | Buy | Goldman |
2/1/2024 | $65.00 → $80.00 | Neutral → Buy | Mizuho |
7/19/2023 | $59.00 | Outperform | Robert W. Baird |
6/30/2023 | $64.00 | Buy | CL King |
5/30/2023 | $58.00 | Overweight | Morgan Stanley |
3/29/2023 | $57.00 | Buy | UBS |
Boston Scientific announces agreement to acquire SoniVie Ltd.
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.
Boston Scientific announces completion of €1.5 billion offering of senior notes
MARLBOROUGH, Mass., Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate principal amount of 3.250% notes due 2034 (collectively, the "Notes"). The Notes are fully and unconditionally guaranteed by the Company. Application has been made for the Notes to be admitted to the Official List of the Irish Stock Exchange plc trading as Euronext Dublin and to trading on the Global Exchange Market thereof.
Boston Scientific announces pricing of €1.5 billion of senior notes
MARLBOROUGH, Mass., Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has priced a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate principal amount of 3.250% notes due 2034 (collectively, the "Notes"). The Notes will be fully and unconditionally guaranteed by the Company. The offering is being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.
Boston Scientific upgraded by Deutsche Bank with a new price target
Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00
Boston Scientific downgraded by Needham
Needham downgraded Boston Scientific from Buy to Hold
Goldman initiated coverage on Boston Scientific with a new price target
Goldman initiated coverage of Boston Scientific with a rating of Buy and set a new price target of $90.00
EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
SVP, GC and Corp. Secretary Brown Vance R sold $486,702 worth of shares (4,826 units at $100.85), decreasing direct ownership by 11% to 41,019 units (SEC Form 4)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
SVP, Global Controller and CAO Woodworth Emily sold $800,897 worth of shares (7,631 units at $104.95) and exercised 5,949 shares at a strike of $37.50, decreasing direct ownership by 80% to 432 units (SEC Form 4)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
SVP, Global Controller and CAO Woodworth Emily exercised 8,055 shares at a strike of $37.78, sold $999,872 worth of shares (9,887 units at $101.13) and covered exercise/tax liability with 355 shares, decreasing direct ownership by 51% to 2,114 units (SEC Form 4)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
SEC Form DEFA14A filed by Boston Scientific Corporation
DEFA14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
SEC Form DEF 14A filed by Boston Scientific Corporation
DEF 14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
Boston Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
March 1, 2024 - FDA Roundup: March 1, 2024
For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide
Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner
BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1. "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued
Boston Scientific announces results for fourth quarter and full year 2024
MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst. Additionally, the company will webcast its
Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)